Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81:75–94.

Article  PubMed  Google Scholar 

Kamat AM, Sylvester RJ, Böhle A, Palou J, Lamm DL, Brausi M, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol. 2016;34:1935–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kamat AM, Colombel M, Sundi D, Lamm D, Boehle A, Brausi M, et al. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol. 2017;14:244–55.

Article  PubMed  Google Scholar 

Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer-a current perspective. Nat Rev Urol. 2014;11:153–62.

Article  CAS  PubMed  Google Scholar 

Ratliff TL, Gillen D, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol. 1987;137:155–8.

Article  CAS  PubMed  Google Scholar 

Kates M, Nirschl T, Sopko NA, Matsui H, Kochel CM, Reis LO, et al. Intravesical BCG induces CD4+ T-cell expansion in an immune competent model of bladder cancer. Cancer Immunol Res. 2017;5:594–603.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol. 1992;147:1636–42.

Article  CAS  PubMed  Google Scholar 

Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol. 1993;150:1018–23.

Article  CAS  PubMed  Google Scholar 

Honda S, Sakamoto Y, Fujime M, Kitagawa R. Immunohistochemical study of tumor-infiltrating lymphocytes before and after intravesical bacillus Calmette-Guérin treatment for superficial bladder cancer. Int J Urol. 1997;4:68–73.

Article  CAS  PubMed  Google Scholar 

Lim CJ, Nguyen PHD, Wasser M, Kumar P, Lee YH, Nasir NJM, et al. Immunological hallmarks for clinical response to BCG in bladder cancer. Front Immunol. 2020;11:615091.

Article  CAS  PubMed  Google Scholar 

Boccafoschi C, Montefiore F, Pavesi M, Pastormerlo M, Annoscia S, Lozzi C, et al. Immunophenotypic characterization of the bladder mucosa infiltrating lymphocytes after intravesical BCG treatment for superficial bladder carcinoma. Eur Urol. 1992;21:304–8.

Article  CAS  PubMed  Google Scholar 

Delcourt C, Gemival P, Nouhaud FX, Gobet F, Gillibert A, Ferlicot S, et al. Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC). World J Urol. 2020;38:1517–24.

Article  CAS  PubMed  Google Scholar 

Hashizume A, Umemoto S, Yokose T, Nakamura Y, Yoshihara M, Shoji K, et al. Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin. Oncotarget. 2018;9:34066–78.

Article  PubMed  PubMed Central  Google Scholar 

Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, et al. Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials. Clin Cancer Res. 2020;26:882–91.

Article  CAS  PubMed  Google Scholar 

Aydin AM, Baydar DE, Hazir B, Babaoglu B, Bilen CY. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy. World J Urol. 2020;38:2537–45.

Article  CAS  PubMed  Google Scholar 

Rodríguez-Izquierdo M, Del Cañizo CG, Rubio C, Reina IA, Hernández Arroyo M, Rodríguez Antolín A, et al. Immune predictors of response after Bacillus Calmette-Guérin treatment in non-muscle-invasive bladder cancer. Cancers. 2023;15:5554.

Article  PubMed  PubMed Central  Google Scholar 

Tran MA, Youssef D, Shroff S, Chowhan D, Beaumont KG, Sebra R, et al. Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment. J Exp Med. 2024;221:e20240045.

Article  CAS  PubMed  Google Scholar 

Salmasi A, Elashoff DA, Guo R, Upfill-Brown A, Rosser CJ, Rose JM, et al. Urinary cytokine profile to predict response to intravesical BCG with or without HS-410 therapy in patients with non-muscle-invasive bladder cancer. Cancer Epidemiol Biomark Prev. 2019;28:1036–44.

Article  CAS  Google Scholar 

Parra Cuentas E. Methods to determine and analyze the cellular spatial distribution extracted from multiplex immunofluorescence data to understand the tumor microenvironment. Front Mol Biosci. 2021;8:668340.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wiśniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6:359–62.

Article  PubMed  Google Scholar 

Nunez-Nateras R, Castle EP, Protheroe CA, Stanton ML, Ocal TI, Ferrigni EN, et al. Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder. Urol Oncol. 2014;32:45.e23–45.e30.

Article  PubMed  Google Scholar 

Pichler R, Gruenbacher G, Culig Z, Brunner A, Fuchs D, Fritz J, et al. Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer. Cancer Immunol Immunother. 2017;66:427–40.

Article  CAS  PubMed  Google Scholar 

Goda N, Sasada S, Shigematsu H, Masumoto N, Arihiro K, Nishikawa H, et al. The ratio of CD8+lymphocytes to tumor-infiltrating suppressive FOXP3+ effector regulatory T cells is associated with treatment response in invasive breast cancer. Discov Oncol. 2022;13:27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liang Y, Lü W, Zhang X, Lü B. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer. Diagn Pathol. 2018;13:93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30:899–911.

Article  CAS  PubMed  Google Scholar 

Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, et al. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 2016;22:679–84.

Article  CAS  PubMed  Google Scholar 

Zlotta AR, Drowart A, Van Vooren JP, de Cock M, Pirson M, Palfliet K, et al. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer. J Urol. 1997;157:492–8.

Article  CAS  PubMed  Google Scholar 

Strandgaard T, Lindskrog SV, Nordentoft I, Christensen E, Birkenkamp-Demtröder K, Andreasen TG, et al. Elevated T-cell exhaustion and urinary tumor DNA levels are associated with Bacillus Calmette-Guérin failure in patients with non-muscle-invasive bladder cancer. Eur Urol. 2022;82:646–56.

Article  CAS  PubMed  Google Scholar 

Strandgaard T, Nordentoft I, Birkenkamp-Demtröder K, Salminen L, Prip F, Rasmussen J, et al. Field cancerization is associated with tumor development, T-cell exhaustion, and clinical outcomes in bladder cancer. Eur Urol. 2024;85:82–92.

Article  CAS  PubMed  Google Scholar 

Hahn NM, O’Donnell MA, Efstathiou JA, Zahurak M, Rosner GL, Smith J. et al. A Phase 1 Trial of Durvalumab in combination with Bacillus Calmette-Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. Eur Urol. 2023;83:486–94.